Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous
Pharma
Roche touts near-complete MS suppression for injectable Ocrevus
Roche's subcutaneous Ocrevus helped 97% of multiple sclerosis patients achieve no relapse up to 48 weeks of treatment.
Angus Liu
Apr 17, 2024 11:00am
Eisai, Biogen's subQ Leqembi delayed amid FDA's data request
Apr 1, 2024 10:45am
BMS touts latest Opdivo data as I-O battle heads to new front
Jan 29, 2024 8:45am
Eisai, Biogen trot out data on injectable Leqembi
Oct 26, 2023 11:59am
BMS's subcutaneous Opdivo measures up to infused version
Oct 19, 2023 11:10am
Roche hits FDA delay with subcutaneous Tecentriq
Sep 7, 2023 2:46pm